Fig. 7.
Fig. 7. Rituximab and complement-mediated lysis of MCLs. / PBMCs from 6 cases of MCL were lysed with rituximab and 25% human serum (black bars) in the presence or absence of blocking anti-CD55 and/or anti-CD59 antibodies (10 μg/mL; hatched bars). Lysis was measured with the Alamar blue assay. The percentage CD20+cells in each sample is also shown (gray bars).

Rituximab and complement-mediated lysis of MCLs.

PBMCs from 6 cases of MCL were lysed with rituximab and 25% human serum (black bars) in the presence or absence of blocking anti-CD55 and/or anti-CD59 antibodies (10 μg/mL; hatched bars). Lysis was measured with the Alamar blue assay. The percentage CD20+cells in each sample is also shown (gray bars).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal